Scarica l'app Stockscreener
13.58
2.51%
-0.35
Dopo l'orario di chiusura:
13.58
Precedente Chiudi:
$13.93
Aprire:
$13.95
Volume 24 ore:
818.49K
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.51B
Reddito:
$-665.00K
Utile/perdita netta:
$-144.74M
Rapporto P/E:
-8.7461
EPS:
-1.5527
Flusso di cassa netto:
$-123.48M
1 W Prestazione:
+2.22%
1M Prestazione:
-22.49%
6M Prestazione:
-7.43%
1 anno Prestazione:
+153.36%
Intervallo 1D:
$13.57
$14.06
Intervallo di 1 settimana:
$12.44
$14.06
Portata 52W:
$4.64
$18.61
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-682-0917
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
13.58 | 1.55B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-03 | Iniziato | Stifel | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Stock: Why the Full Pipeline Story Matters - MarketBeat
Guggenheim Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus - MSN
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer FRATES JAMES M - Moomoo
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress - Insider Monkey
AMLX News | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals, Inc.Common Stock (NQ: AMLX - FinancialContent
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal - Yahoo Finance
Number of shareholders of Amylyx Pharmaceuticals, Inc. – BOATS:AMLX - TradingView
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A - Stock Titan
Amylyx publishes phase 2 Wolfram syndrome trial results - Investing.com
Amylyx publishes phase 2 Wolfram syndrome trial results By Investing.com - Investing.com Nigeria
Contributor: Fuel drug development, not Big Pharma's profits - AOL.com
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation - Business Wire
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - MSN
Amylyx (AMLX) Q1 2026 Earnings Transcript - AOL.com
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus - inkl
Earnings call transcript: Amylyx Pharmaceuticals Q1 2026 earnings miss impacts stock By Investing.com - Investing.com South Africa
Earnings call transcript: Amylyx Pharmaceuticals Q1 2026 earnings miss impacts stock - Investing.com
Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
TradingKey - TradingKey
Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap - Sahm
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN) - The Globe and Mail
Amylyx Pharmaceuticals (NASDAQ:AMLX) Cut to Sell at Wall Street Zen - MarketBeat
MSN Money - MSN
Amylyx Pharmaceuticals Charts Path to 2026 Trial Data - TipRanks
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Amylyx Pharmaceuticals 1Q Loss/Shr 37c >AMLX - Moomoo
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results - BioSpace
Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target - TipRanks
Earnings call transcript: Amylyx Pharmaceuticals Q1 2026 misses EPS forecast - Investing.com
Amylyx Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
AMLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data - ChartMill
Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss - marketscreener.com
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):